August 29, 2018


Media & events


Lyndra Therapeutics Announces Notice of Allowance on Patent Covering Long-acting Pill

December 10, 2018
Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for intellectual property (IP) related to Lyndra’s ultra-long-acting oral...
Read More
1 10 11 12 13 14 18



Lyndra Named as Scrip Award Finalist in Two Categories

Happy to announce our ultra-long acting oral dosage form has been named a finalist for the Scrip MSD Innovation Award, and our co-founder Amy Schulman has been named a finalist in the Executive of the Year category!


Amy Schulman, Lyndra Co-founder and CEO, honored on 2019 PharmaVOICE 100

“Amy’s fearless approach to create durable value and change the trajectory of compliance for some of most difficult to treat diseases —  Alzheimer’s disease, HIV, opioid use disorder, and schizophrenia — are just a couple of the reasons she has been identified as one of the 100 most inspiring people in the life-sciences industry,” says Taren Grom, editor, PharmaVOICE


2019 Xconomy Awards Finalist in Startup Category

We are honored to be named a finalist for the Awards in the category for our work making daily pills a thing of the past.



Lyndra Presents @ BIO International

Join us on Thursday, June 5th, at 5pm when Andrew Bellinger, our CSO, presents our 2019 Company Update at BIO International, Philadelphia Convention Center, Theater 4

2019 BIO International